Important note: Information in this article was accurate in March 2002. The state of the art may have changed since the publication date. 
Report from the 9th annual Retrovirus Conference
Highly active antiretroviral therapy (HAART) has dramatically decreased AIDS-related deaths in North America and Western Europe. Despite this benefit, some people with HIV/AIDS (PHAs) in these regions can still develop serious complications. It is therefore important that long-term monitoring of HAART-users be conducted to find out the following:
One team of researchers at the National Institutes of Health (NIH) and elsewhere in the United States have begun this work and we report on their results.
Researchers collected data from 3,227 HIV positive subjects who participated in several clinical trials between the years 1996 and 2001. They had the following profile:
On average, subjects were monitored for about 1½ years and they received HAART once they enrolled in a clinical trial.
The NIH researchers analysed their data, in part, by collecting information on the number of "AIDS-related events" such as AIDS-related infections. They also collected data on serious or life-threatening complications (which they called "grade IV events"). These complications included such events as bone marrow damage, inflamed pancreas glands, liver-related problems and so on. In analysing their data, here is what the researchers found that occurred over the course of their study:
As a proportion of the study population, the figures can be expressed as follows:
Thus, grade IV events were twice as common as AIDS-related illnesses.
After about 30 months, about 10% of subjects died. The risk of death from AIDS or a grade IV event was about equal. This attests to the severity of such complications. Although PHAs who had more than 200 CD4+ cells had a relatively low risk of developing AIDS (6%), their risk of developing a grade IV event was about four times greater (26%).
The most common grade IV event was complications from liver disease, related to hepatitis virus infection. Other common problems included:
Unfortunately, researchers were unable to find out the cause(s) of the grade IV events reported. Indeed, it is important to remember that many factors can play a role in the development of grade IV events, including the following:
Researchers were also unable to make a link between specific HAART regimens and grade IV events.
This large American study points to the need for conducting more carefully designed long-term studies of anti-HIV therapies to help find out how different therapies affect survival and the development of serious complications (grade IV events). This would better clarify the risks and benefits of specific anti-HIV therapies.
REFERENCE
Reisler R, Han C, Burman W, et al. Incidence of grade IV events, AIDS and mortality in a large multicenter cohort receiving HAART. Abstract 36.
20020319
CATE-N20020303
Copyright © 2002 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284 http://www.catie.ca
ÆGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
